HCW Biologics Inc (HCWB)vsJohnson & Johnson (JNJ)
HCWB
HCW Biologics Inc
$1.08
-6.09%
HEALTHCARE · Cap: $2.57M
JNJ
Johnson & Johnson
$276.32
+3.81%
HEALTHCARE · Cap: $657.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 1477835% more annual revenue ($99.33B vs $6.72M). JNJ leads profitability with a 16.2% profit margin vs -83.1%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
HCWB
Hold41
out of 100
Grade: D
JNJ
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HCWB.
Margin of Safety
-89.3%
Fair Value
$144.28
Current Price
$276.32
$132.04 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 1970.0% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -28.3% — below average capital efficiency
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : HCWB
The strongest argument for HCWB centers on Price/Book, Revenue Growth. Revenue growth of 1970.0% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bear Case : HCWB
The primary concerns for HCWB are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Key Dynamics to Monitor
HCWB profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
HCWB carries more volatility with a beta of 2.27 — expect wider price swings.
HCWB is growing revenue faster at 1970.0% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 41/100), backed by strong 16.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
HCW Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
HCW Biologics Inc is a forward-thinking biotechnology company focused on pioneering immunotherapies and vaccine technologies to tackle pressing health issues such as cancer and infectious diseases. Utilizing its proprietary platforms to amplify immune responses, HCW Biologics is actively expanding a promising pipeline of clinical candidates poised to make significant impacts in patient care. With a keen commitment to strategic partnerships and addressing urgent medical needs, the company aims to establish itself as a competitive force in the biotechnology landscape, presenting compelling investment opportunities that align with the evolving dynamics of the healthcare sector.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?